Medovate has announced that it has entered into an agreement with Mercury Medical for exclusive distribution of the FDA-cleared device SAFIRA.
CLEARWATER, FL / ACCESSWIRE / February 9, 2022 / Medovate, a UK based medical device development company, has announced that it has entered into an agreement with Mercury Medical for exclusive distribution of the FDA-cleared device SAFIRA® (SAFer Injection for Regional Anesthesia) across the whole of the United States (US).
Left to right: Ray Mundy, Executive Vice President Sales & Marketing, Mercury Medical Chris Rogers, Sales & Marketing Director, Medovate George E. Howe, Jr., Executive Vice President, Mercury Medical Jim Beyer, US Commercial Executive Consultant, Medovate
The agreement also includes the newly launched SAFIRA® Palm Operator which has been launched in the US market to offer anesthesiologists more versatility and choice when using the SAFIRA® regional anesthesia system.
In California Mercury Medical will also be distributing the SAFIRA® NRFit™ syringe, which provides an alternative to the Luer connection syringes with which the SAFIRA® system was originally introduced, further enhancing the system’s revolutionary benefits for patient safety.
Stuart Thomson, Managing Director of Medovate, said: “As our company grows, it has been our vision to centralise our USA distribution with a primary distributor to streamline processes and provide a single contact point for clinicians in the US interested in SAFIRA®. Mercury Medical have positioned themselves as a US leader in providing technological advances for clinicians in both airway solutions and anesthesia - a philosophy that aligns very well with Medovate and SAFIRA®. We are excited to this partnership with them as primary distributor of our SAFIRA® system in the USA and look forward to entering this next phase of our journey.”
Developed with clinicians working in the UK’s NHS to promote safer injection during single shot regional anesthesia peripheral nerve block procedures, the SAFIRA® system transforms regional anesthesia into a one-person procedure, giving the anesthesiologist full control of the injection at all times. It also includes a built-in safety mechanism to automatically limit injection pressure helping to reduce the risks of nerve damage, promoting patient safety.
Medovate has a co-promotional partnership agreement with Konica Minolta Healthcare Americas Inc. to promote best practice in ultrasound guided regional anesthesia across the US. Mercury Medical is also an appointed distributor for the Konica Minolta SONIMAGE HS2 portable ultrasound system, complementing their appointment as primary distributor of Medovate’s SAFIRA® technology.
Dr John Gargaro, President and CEO at Mercury Medical, said: SAFIRA represents a superior solution by providing efficiency with integrated safety features designed to improve outcomes for patients receiving regional anesthesia. As a company, Mercury Medical has a rich experience in introducing and training clinicians on innovative, clinically differentiated medical devices. We are well positioned to provide the central point of contact for all of Medovate’s US sales and distribution requirements for a product offering that perfectly aligns with our mission.”
This year Mercury Medical will be attending the 47th Annual Regional Anesthesiology and Acute Pain Medicine Meeting, organised by the American Society of Regional Anesthesia and Pain Medicine (ASRA), to showcase the SAFIRA® system. The meeting is one of the largest events for regional anesthesia professionals in the US and will be held March 31 - April 2, 2022, at Caesars Palace in Las Vegas, Nevada.
Over 20 million regional anesthetic nerve blocks are performed each year throughout the EU and US (1). As the use of regional anesthesia continues to grow globally, the SAFIRA® system for safer injection during regional anesthesia provides a unique offering to anesthesiologists and their patients and has the potential to make a significant impact on improving patient safety in the US.
1. Fong-Soe-Khioe R. Health Economic report Medovate commissioned written by a health economist from the University of East Anglia (UEA)
About Mercury Medical www.mercurymed.com
For over 58 years clinicians have relied on Mercury Medical as their resource for bringing a legacy of innovative products to critical care areas of neonatal, anesthesia, respiratory and EMS markets in over 60 countries. Mercury Medical’s high-quality standards include ISO 13485, MDSAP and ISO 9001 certifications.
For more information:
Contact Lisa Cordner
Phone/Fax #: (727) 573-4930
E-mail Address: lcordner@mercurymed.com
www.mercurymed.com
About Medovate www.medovate.co.uk
Medovate is a medical device company dedicated to the development and commercialisation of innovative medical technologies created within the NHS and beyond. Medovate identifies and works with high potential medtech innovations, providing the specialist management and technical resources to guide medical technologies through development, clinical trials, regulatory approval, into manufacture and on through to successful market launch. Medovate accelerates medical device innovations to market in order to benefit patient care and healthcare delivery. The company has a strong portfolio relating to specialisms in anaesthesia, airway management, critical care and surgery. Medovate provides commercial returns to the NHS organisations and inventors that created the technologies helping to support further NHS innovation.
Notes:
For more information, to request images or to arrange for a SAFIRA SAFer Regional Anesthesia system demonstration, please contact: Julia Price: julia.price@medovate.co.uk, 07737 864 878
SOURCE: Mercury Medical
View source version on accesswire.com:
https://www.accesswire.com/688000/Medovate-Announces-Exclusive-US-Distribution-Agreement-with-Mercury-MedicalR-for-SAFIRAR
